Ear­ly da­ta on NextCure's im­muno-on­col­o­gy drug in lung can­cer pa­tients de­lights in­vestors

Shares of fresh­ly pub­lic biotech NextCure sky­rock­et­ed on Tues­day af­ter the com­pa­ny pub­lished an ab­stract high­light­ing ini­tial da­ta from an ear­ly-stage study of its sole ex­per­i­men­tal im­muno-on­col­o­gy drug.

The ther­a­py, NC318, is en­gi­neered to in­hib­it Siglec-15 (S15), a key im­mune sup­pres­sor in cer­tain can­cer pa­tients whose tu­mors are re­sis­tant to the ex­ist­ing raft of check­point in­hibitors. S15 is found on cer­tain myeloid cells in the tu­mor mi­croen­vi­ron­ment and on cer­tain tu­mor types in­clud­ing lung, ovar­i­an and head, and neck can­cers.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN